MONTREAL, QUEBEC -- (MARKET WIRE) -- December 05, 2006 -- Ambrilia Biopharma Inc. (TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases, announced today further distribution partnerships for the sales and marketing in Europe of its improved sustained-release formulation of Octreotide for the treatment of acromegaly. No financial terms are released.
